Easy NAPLEX Diabetes Case Practice Questions

Concept Explanation

An Easy NAPLEX Diabetes Case involves the clinical application of glycemic targets, medication selection, and patient education principles for individuals with Type 1 or Type 2 Diabetes Mellitus. Managing these cases requires a foundational understanding of the American Diabetes Association (ADA) Standards of Care, which emphasize individualized A1c goals and the selection of pharmacotherapy based on patient-specific factors such as cardiovascular risk and renal function. For most non-pregnant adults, the standard glycemic target is an A1c of $< 7\%$, with a pre-prandial blood glucose range of $80-130 \text{ mg/dL}$ and a peak post-prandial glucose of $< 180 \text{ mg/dL}$.

Pharmacists must be proficient in identifying the mechanism of action, common side effects, and contraindications for first-line agents like metformin, as well as newer classes like SGLT2 inhibitors and GLP-1 receptor agonists. Mastering these basics is essential for success on the NAPLEX Prep journey. When reviewing a patient case, always evaluate the patient's current renal function using the Cockcroft-Gault equation to determine if medications like metformin (contraindicated if eGFR $< 30 \text{ mL/min/1.73m}^2$) are safe to continue. You can also use our AI Lecture Notes Enhancer to summarize complex drug tables into manageable study guides.

Solved Examples

Example 1: Calculating Insulin Sensitivity Factor (ISF)
A patient with Type 1 Diabetes uses 50 units of total daily insulin (TDI). Using the "1800 Rule" for rapid-acting insulin, calculate the point drop in blood glucose per unit of insulin.

1. Identify the rule: The 1800 Rule is used for rapid-acting insulin (Lispro, Aspart).
2. Apply the formula: $$\text{ISF} = \frac{1800}{ \text{TDI}}$$
3. Substitute the values: $$\text{ISF} = \frac{1800}{50} = 36$$
4. Conclusion: 1 unit of rapid-acting insulin will drop the blood glucose by approximately $36 \text{ mg/dL}$.

Example 2: Metformin Contraindications
A 65-year-old male with a history of T2DM has a serum creatinine (SCr) of $1.8 \text{ mg/dL}$. His calculated eGFR is $28 \text{ mL/min/1.73m}^2$. Should metformin be initiated?

1. Review the eGFR threshold: Metformin is contraindicated in patients with an eGFR $< 30 \text{ mL/min/1.73m}^2$.
2. Compare the patient's value: $28 < 30$.
3. Conclusion: Metformin should not be initiated due to the high risk of lactic acidosis.

Example 3: Correcting Hypoglycemia
A patient experiences shakiness and a blood glucose reading of $62 \text{ mg/dL}$. How should this be treated according to the "Rule of 15"?

1. Identify the initial treatment: Consume $15 \text{ grams}$ of fast-acting carbohydrates (e.g., 4 oz juice, 3-4 glucose tablets).
2. Wait period: Wait 15 minutes and recheck blood glucose.
3. Action if still low: If glucose is still $< 70 \text{ mg/dL}$, repeat the $15 \text{ grams}$ of carbs.
4. Final step: Once glucose is normal, consume a small snack or meal to prevent a recurrence.

Practice Questions

1. A 54-year-old female with T2DM and a history of heart failure (HFrEF) has an A1c of $8.2\%$ despite taking metformin $1,000 \text{ mg}$ BID. Which medication class is specifically recommended to be added next based on her comorbidities?

2. A patient is prescribed Bydureon (Exenatide ER). What is the frequency of administration for this specific formulation?

3. Calculate the Insulin-to-Carbohydrate Ratio (ICR) for a patient using 60 units of total daily insulin (TDI) using the "500 Rule."

4. Which insulin is typically cloudy in appearance and should be rolled gently before use?

5. A patient with an A1c of $9.5\%$ is being started on Basaglar. What is the standard starting dose for basal insulin in a T2DM patient using weight-based dosing ($0.1-0.2 \text{ units/kg}$) if the patient weighs $80 \text{ kg}$?

6. Identify the primary side effect associated with SGLT2 inhibitors like empagliflozin related to the urinary tract.

7. A patient is switching from NPH insulin BID to Insulin Glargine once daily. What dose reduction, if any, is recommended during this conversion?

8. Which class of diabetes medications carries a boxed warning for the risk of thyroid C-cell tumors?

9. A patient is currently taking Januvia (Sitagliptin). The physician wants to add Victoza (Liraglutide). Why is this combination generally avoided?

10. What is the target pre-prandial blood glucose range for a non-pregnant adult with diabetes according to ADA guidelines?

Answers & Explanations

1. Answer: SGLT2 Inhibitor. According to the cardiovascular pharmacology guidelines, SGLT2 inhibitors have proven benefits in reducing heart failure hospitalizations and are preferred in patients with HFrEF.
2. Answer: Once weekly. Bydureon is the extended-release formulation of exenatide and is administered once every seven days, unlike the immediate-release Byetta, which is twice daily.
3. Answer: $8 \text{ grams}$. Using the formula $$\text{ICR} = \frac{500}{ \text{TDI}} = \frac{500}{60} = 8.33$$, which is rounded to $8 \text{ grams}$ of carbohydrates covered by 1 unit of insulin.
4. Answer: NPH (Neutral Protamine Hagedorn). NPH is an intermediate-acting insulin that is a suspension, giving it a cloudy appearance. It must be resuspend by rolling the vial.
5. Answer: $8-16 \text{ units}$. Calculation: $$80 \text{ kg} \times 0.1 = 8 \text{ units}$$ and $$80 \text{ kg} \times 0.2 = 16 \text{ units}$$.
6. Answer: Genital mycotic infections (yeast infections) and UTIs. Because SGLT2 inhibitors promote glucose excretion in the urine (glucosuria), they create an environment conducive to fungal and bacterial growth.
7. Answer: $20\%$ dose reduction. When converting from NPH dosed BID to glargine once daily, the total daily dose of NPH should be reduced by $20\%$ to lower the risk of hypoglycemia.
8. Answer: GLP-1 Receptor Agonists. This class (except for lixisenatide) includes a boxed warning regarding the risk of thyroid C-cell tumors, based on rodent studies.
9. Answer: Overlapping mechanism of action. Both DPP-4 inhibitors (Januvia) and GLP-1 agonists (Victoza) act on the incretin pathway. Using them together provides no additional efficacy and increases cost and potential side effects. You can find more details in our diabetes medication practice guide.
10. Answer: $80-130 \text{ mg/dL}$. This is the standard target for most adults to minimize long-term microvascular complications.

1. Which medication should be discontinued if a patient's eGFR drops to 25 mL/min/1.73m²?

• AGlipizide
• BMetformin
• CPioglitazone
• DLinagliptin

Frequently Asked Questions

What is the first-line treatment for Type 2 Diabetes?

Metformin is considered the first-line pharmacological treatment for Type 2 Diabetes due to its high efficacy, low cost, and weight-neutral profile. It should be initiated along with lifestyle modifications unless there are specific contraindications like advanced renal disease.

How do SGLT2 inhibitors help with heart failure?

SGLT2 inhibitors reduce preload and afterload through osmotic diuresis and natriuresis, which decreases the workload on the heart. Clinical trials have shown they significantly reduce the risk of hospitalization for heart failure in patients with and without diabetes.

When should a patient use the 1800 Rule versus the 1500 Rule?

The 1800 Rule is used for patients using rapid-acting insulins like Lispro or Aspart to calculate the insulin sensitivity factor. The 1500 Rule is reserved for patients using regular human insulin for their bolus doses.

Can GLP-1 agonists be used in patients with a history of pancreatitis?

GLP-1 receptor agonists have been associated with a potential risk of acute pancreatitis in post-marketing reports. While not an absolute contraindication, they should be used with caution and avoided in patients with a known history of pancreatitis.

What is the difference between Basaglar and Lantus?

Basaglar and Lantus both contain Insulin Glargine 100 units/mL and are biologically similar. Basaglar was approved as a follow-on biologic, meaning it provides the same long-acting glucose control but is often a more cost-effective option for many patients.